denileukin diftitox-cxdl

$Representative image of a biotechnology commercialization and oncology finance setting, reflecting Citius Oncology’s up to $36.5 million capital raise to support the United States launch of LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma.$

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
Zynga
Zynext Ventures USA LLC

Pharma Industry News

Citius Oncology (CTOR) stock in focus as $36.5m financing targets LYMPHIR commercialization

Citius Oncology has capital and an approved CTCL drug. The harder question is whether LYMPHIR can turn niche oncology promise into revenue.

May 6, 2026